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Abstract
Introduction: Multi-drug resistant tuberculosis (MDR TB) is a significant health problem in some parts of the world. Three major 
cytokines involved in TB immunopathogenesis include IL-2, IL-4 and IL-10. The susceptibility to MDR TB may be genetically 
determined. The aim of the study was to assess the association of IL-2, IL-4, IL-10 gene polymorphisms with multi-drug resistant 
tuberculosis (MDR TB) in Ukrainian population.
Material and methods: We observed 140 patients suffering from infiltrative pulmonary tuberculosis (PT) and 30 apparently 
healthy subjects. The patients were assigned to two groups whether they suffer or do not suffer from pulmonary MDR TB. In-
terleukin gene (IL) polymorphisms, particularly T330G polymorphism in the IL-2 gene, C589T polymorphism in the IL-4 gene and 
G1082A polymorphism in the IL-10 gene were studied through polymerase chain reaction. Circulating levels of IL-2, IL-4 and IL-10 
in venous blood were estimated using ELISA.
Results: Prior to treatment, patients with PT showed significant increase of IL-2 levels and decrease of IL-4 and IL-10 levels com-
pared to apparently healthy subjects. Circulating IL-4 and IL-10 levels were significantly decreased whilst serum IL-2 level was 
significantly increased in patients with MDR TB compared to non-MDR TB. Low IL-4 and IL-10 secretion and considerable IL-2 alter-
ations were shown to be significantly associated with mutations of homozygous and heterozygous genotypes affecting C589T poly-
morphism in the IL-4 gene, G1082A polymorphism in the IL-10 gene and T330G polymorphism in the IL-2 gene in patients with PT. 
Conclusions: Heterozygous genotype and mutations homozygous genotypes gene in polymorphisms determining specified 
cytokines’ production is a PT risk factor and may lead to disease progression into chronic phase. Heterozygous genotype of 
aforementioned cytokine genetic polymorphisms was significantly the most frequent in patients with MDR TB.
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Introduction
Mycobacterium tuberculosis (MTB) resis-
tance to antimycobacterial drugs is a problem 
of immediate interest worldwide [1]. Experts 
generally agree that the prevalence of multi-drug 
resistant tuberculosis (MDR TB) has become un-
controlled all over the world; and some countries 
even consider MDR TB as a  threat to national 
security [2, 3]. There is a  growing number of 
strains that are resistant to one or more anti-TB 
drugs constituting the main cause for decreasing 
efficiency of chemotherapy, increasing number 
of patients with destructive forms, increasing 
frequency of significant residual post-tuberculosis 
alterations and increasing incidence of TB relaps-
es. Therefore, an unfavorable epidemiological 
background for further spread of TB infection 
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may occur [4, 5]. TB incidence associated with 
multi-drug resistance grows year by year [6].
The real cause why some patients infected 
with MTB develop the disease accompanied by 
nonstable immunological response whilst the oth-
ers demonstrate efficient immunogenic reaction 
intended to limit pathogen dissemination and 
prevent the disease remains unclear. Heredity 
impact on TB development was established in 
the studies of monozygotic and dizygotic twins. 
Thus, some evidence indicating that genetics may 
contribute into susceptibility to TB infection was 
obtained [7−9]. 
Multifaceted interaction between pathogen 
and human immune system is a key factor influ-
encing disease development and progression as 
well as the efficiency of applied treatment in pa-
tients with TB. Cytokines represent an important 
immunologic agents in MTB control. Three major 
cytokines involved in TB immunopathogenesis 
include IL-2, IL-4 and IL-10 [10−13].
There is clear evidence that genetic peculiar-
ities of a human being largely determine suscep-
tibility to infection. Hence, a significant number 
of patients infected with MTB are apparently 
healthy subjects who developed an adequate pro-
jective immunity whereas only 5−10% of people 
have inefficient immunological response that may 
lead to TB development [14].
Human susceptibility to MTB as an infectious 
antigen is encoded in various genes with different 
influence on pathologic phenotype development. 
Distribution of genotypes predisposed to higher 
risk of MTB infection and TB development or 
resistant to these factors is unique for every popu-
lation and may be the reason for diverse immune 
response to infectious agent [15].
Moreover, genetic regulation is a complex 
process of multiple genetic sites correlation [16]. 
Gene polymorphisms and protein products in-
volved in immunologic protective response de-
termine the degree of MTB resistance as well as 
disease severity and duration [17, 18].
Th1-lymphocytes producing IL-2 play a pro-
tective role in TB immunopathogenesis, whereas 
Th2-lymphocytes producing IL-4 and IL-10 help 
to maintain function of Th1-lymphocytes. Th1/
Th2-lymphocytes are deemed not to be able to 
eliminate MTB from human body, probably due to 
inadequate cellular immune response. Consequent-
ly, humoral immune response occurs [10, 19−21].
Considering functional role of IL-2, IL-4 and 
IL-10 as well as potential genetic variability of 
polymorphic variants, the study objective was 
to investigate whether IL-2, IL-4 and IL-10 gene 
polymorphisms are associated with MDR TB in 
Ukrainian population.
Material and methods
We observed 140 Caucasian patients with 
infiltrative pulmonary TB permanently residing 
in Kharkiv and Kharkiv region, Ukraine, aged be-
tween 20 and 70 years. The patients were assigned 
to two groups whether they suffer or do not suffer 
from pulmonary MDR TB: the first group — 74 
patients with MDR TB, the second group — 66 
patients not suffering from MDR TB (non-MDR 
TB). Patients were recruited at the Regional TB 
Hospital no 1 and Regional Anti-TB Dispensary no 
1 both in Kharkiv; Regional Anti-TB Dispensary 
no 3 in Zmeev and Anti-Regional TB Dispensary 
no 4 in Izyum, both in Kharkiv region. All pa-
tients suffered from infiltrating pulmonary TB. 
All patients were HIV-negative.
The third control group included 30 appar-
ently healthy subjects with comparable age char-
acteristics, no positive history of pulmonary dis-
ease, no pathological findings in lungs according 
to chest X-ray examination, no chronic infectious 
disease, no acute allergic reactions and respirato-
ry diseases for 3 months prior to the study. 
Venous blood sampling was performed in 
the morning (between 8 and 9 a.m.) on the first 
days of hospitalization and following two months 
of patient’s staying at hospital. Serum cytokine 
(IL-2, IL-10 and IL-4) levels were measured using 
standard ELISA kits.
Molecular methods: Genomic DNA was 
extracted from blood samples with the «DNA 
Express» (Liteh Company, Moscow, Russia), 
according to the manufacturer’s  instructions. 
The sets with primers were purchased from Liteh 
Company (Moscow, Russia) and used it according 
to the manufacturer’s instructions. The method 
of investigation (for the sets real-time) — an 
allele-specific PCR using intercalating coloring 
SybrGreen. T330G — IL-2 rs2069762, C589T — 
IL-4 rs2243250 and G1082A — IL-10 rs1800896 
were genotyped with amplification-refractory 
mutation system-polymerase chain reaction 
(ARMS-PCR).
Statistics packages MicrosoftExel and Sta-
tistica 7.0 were used for statistical analysis. 
Pearson’s chi-square test with Yates’ correction 
for continuity was used to determine if the data 
are normally distributed. Data received were 
analyzed using Student’s t-test. The mean values 
were considered to be significantly different at 
p < 0.05. Data calculation was also performed 
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Table 1.  Serum interleukins’ levels in patients with pulmonary tuberculosis prior to and following two months  
of antituberculosis chemotherapy compared with apparently healthy subjects (mean ± m), pg/l
Groups N
case
Interleukin-2 Interleukin-4 Interleukin-10
Before  
treatment
After 
2 months of 
treatment
Before  
treatment
After 
2 months of 
treatment
Before  
treatment
After 
2 months of 
treatment
1st group — 
with MDR TB
74 39.34 ± 
1.14**$
32.85 ± 
1.11**#$
7.96 ± 
0.29**$
17.62 ± 
0.54**#$
38.01 ± 
0.78**$
44.58 ± 
0.78****#
2nd group — 
without MDR TB
66 36.20 ± 
0.89**
25.27 ± 
0.65**#
11.29 ± 
0.35**
21.40 ± 
0.60**#
43.88 ± 
0.70**
50.59 ± 
0.99*#
3rd group —
healthy donors
30 21.60 ± 0.80 29.99 ± 1.27 50.25 ± 1.26
*discrepancy is not significant (p > 0.05) when compared with Group 3 
**discrepancy is significant (p < 0.001) when compared with Group 3 
#discrepancy is significant (p < 0.001) when compared before treatment and after two months levels among Group
$discrepancy is significant (p < 0.001) between Groups 1 and 2
using the relative risk (RR) with 95% probability 
interval estimation [22].
The project was approved by the Ethics 
Committee of the Kharkiv National Medical 
University, Ukraine. It was conducted according 
to the principles established in the Declaration 
of Helsinki. Every patient has signed written 
informed consent and has given his assent for 
DNA and blood tests as well as relevant clinical 
data collection.
Results
Statistically significant increase of serum 
IL-2 concentration was observed in patients with 
TB compared to the healthy subjects (p < 0.05). 
Serum IL-2 level significantly decreased in pa-
tients with pulmonary TB following two months 
of routine treatment compared to IL-2 level prior 
to treatment. Circulating IL-2 concentration was 
significantly increased in patients with pulmo-
nary TB following two months of treatment in 
comparison with the healthy subjects (Table 1).
It was shown that homozygous (GG) and hete-
rozygous (TG) genotypes of T330G polymorphism 
in the IL-2 gene are the most frequent in patients 
with pulmonary TB (c2 = 34.60, p < 0.01). Homo-
zygous (TT) genotype of the IL-2 gene was the less 
frequent genetic variant in TB patients. Homozy-
gous (TT) genotype of the IL-2 gene was frequent 
in healthy subjects (p < 0.01) (Table 2). Estimation 
of relative risk of pulmonary TB development has 
revealed that carriers of homozygous (GG) or hetero-
zygous (TG) genotypes of T330G polymorphism in 
the IL-2 gene (RR = 1.87, [1.32; 2.64], p < 0.05) are 
at 1.87 times higher risk to develop the disease than 
carriers of homozygous genotype (TT) (Table 2).
Investigating TB resistance, we observed 
a  significant prevalence of heterozygous (TG) 
genotype in the IL-2 gene in the MDR TB group 
compared to the non-MDR TB group. However, 
homozygous (GG) genotype of the IL-2 gene was 
the most frequent in patients not suffering from 
MDR TB (c2 = 52.84, p < 0.01). Relative risk of 
MDR TB development in carriers of heterozy-
gous (TG) genotype of the IL-2 gene is 5.22 times 
higher than in carriers of homozygous (GG and 
TT) genotypes of the IL-2 gene (RR = 5.22, [2.74; 
9.96], p < 0.05).
We observed statistically significant decre-
ased serum levels of anti-inflammatory cytokines 
IL-4 and IL-10 compared with the healthy subjects 
at the point of treatment onset (p < 0.05). The 
IL-4 and IL-10 levels were significantly increased 
in patients with TB compared to the point of 
treatment onset. Although IL-10 concentrations 
significantly increased during the first two mon-
ths of treatment in both TB groups, it was still 
lower in MDR TB group than that in the controls 
(Table 1). Serum IL-4 and IL-10 levels were si-
gnificantly lower in patients with MDR TB prior 
to chemotherapy and following two months of 
treatment compared with the non-MDR TB group.
The study revealed correlation between circu-
lating inflammatory cytokines concentrations or 
level alterations and genotypes of polymorphisms 
in the IL-4 and IL-10 genes in the relevant groups 
of patients with pulmonary TB (Table 2). Our 
study of C589T and G1082A polymorphisms has 
shown the prevalence of mutational homozygous 
and heterozygous genotype polymorphisms of the 
IL-4 and IL-10 genes in patients with pulmonary 
TB (IL-4 – c2 = 24.71 and IL-10 – c2 = 34.14, p < 
0.01). Polymorphisms of the IL-4 and IL-10 genes 
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Table 2. Distribution of polymorphism genotypes of interleukins in patients with pulmonary tuberculosis and healthy subjects
Genotype 
Groups
Gene IL-2 
polymorphisms T330G
Gene IL-4 
polymorphism C589T
Gene IL-10 
polymorphism G1082A
TG GG TT CT TT CC GA АА GG
1st group — 
with MDR TB
(N case = 74)
n 59 8 7 53 11 10 56 11 7
% 79.73 ± 
4.67*#^
10.81 ± 
3.61&^^
9.46 ± 
3.40●
71.62 ± 
5.24*#^
14.86 ± 
4.14&^^
13.51 ± 
3.97●
75.68 ± 
4.99*#^
14.86 ± 
4.14&^^
9.46 ± 
3.40●
2nd group —
without MDR TB
(N case = 66)
N 13 43 10 9 46 11 17 41 8
% 19.70 ± 
4.90*
65.15 ± 
5.87**
15.15 ± 
4.41$
13.64 ± 
4.22*
69.70 ± 
5.66**
16.67 ± 
4.59$
25.76 ± 
5.38*
62.12 ± 
5.97**
12.12 ± 
4.02#
3rd group —
healthy donors
(N case = 30)
N 5 7 18 7 6 17 7 6 17
% 16.67 ± 
6.80#
23.33 ± 
7.72**
60.00 ± 
8.94
23.33 ± 
7.72#
20.00 ± 
7.30**
56.67 ± 
9.05
23.33 ± 
7.72#
20.00 ± 
7.30**
56.67 ± 
9.05
*discrepancy is significant (p < 0.05) when comparing between mutation homozygote and heterozygous genotype in group 
**discrepancy is significant (p < 0.05) when comparing between mutation and normal homozygote in group 
#discrepancy is significant (p < 0.05) when comparing between normal homozygote and heterozygous genotype in group 
$discrepancy is not significant (p > 0.05) when comparing between normal homozygote and heterozygous genotype in group 
&discrepancy is not significant (p > 0.05) when comparing between mutation and normal homozygote in group 
^discrepancy is significant (p < 0.05) when comparing heterozygous genotype between 1st and 2nd group 
^^discrepancy is significant (p < 0.05) when comparing mutation homozygote between 1st and 2nd group 
●discrepancy is not significant (p > 0.05) when comparing normal homozygote between 1st and 2nd group
can result in IL-4 and IL-10 level alterations in 
patients with infiltrative pulmonary TB detected 
on admission to hospital as well as following two 
months of treatment. Moreover, we demonstra-
ted that carriers of mutational homozygous or 
heterozygous genotype of C589T polymorphism 
in the IL-4 gene and polymorphism G1082A in 
the IL-10 gene are at 1.63 times (IL-4) and 1.93 
times (IL-10) higher risk to develop the TB than 
carriers of normal genotype without aforemen-
tioned polymorphisms in the genes encoding 
anti-inflammatory cytokines (IL-4 – RR = 1.63, 
[1.21; 2.18], p < 0.05) and IL-10 – RR = 1.93, 
[1.33; 2.80], p < 0.05).
At studied C589T polymorphism genotypes 
of the IL-4 gene and G1082A polymorphism ge-
notypes of the IL-10 gene we found a significant 
difference associated with resistant pulmonary 
TB. Specifically, heterozygous genotype (CT) of 
the IL-4 gene and heterozygous genotype (GA) of 
the IL-10 gene were the most frequent in MDR 
TB patients group compared with the non-MDR 
TB group of patients (IL-4 – c2 = 52.33 and IL-10 
– c2 = 37.69, p < 0.01). Heterozygous genotype 
(CT) of the IL-4 gene and heterozygous genotype 
(GA) of the IL-10 gene were 4.43 times and 3.62 
times more frequent than homozygous genotype 
respectively in patients with MDR TB (IL-4 – RR 
= 4.43, [2.58; 7.60], p < 0.05; and IL-10 – RR = 
3.62, [2.11; 6.22], p < 0.05). These peculiarities 
were also detected in the non-MDR TB group of 
patients.
Discussion
It is well known that alterations in gene 
promoter region lead to modification of its tran-
scriptional activity. T330G polymorphism located 
in the IL-2 promoter region should technically 
result in amino acid replacement in protein su-
bunits corresponding to these polymorphic genes, 
in relation to origin of transcription and influence 
the level of gene expression and relevant prote-
in level. Analysis of association between IL-2 
secretion and allelic variant of T330G polymor-
phism in the IL-2 gene has shown that patients 
with TB have a statistically significant increase 
of serum IL-2 concentration compared to the 
third group. These changes may correspond to 
undifferentiated reaction of immune response to 
MTB elimination. It is well known that IL-2 has 
an impact on macrophages activation and direct 
cytotoxicity of T-cells, which accounts for protec-
tive role of IL-2 against tuberculosis [23]. On the 
contrary, it supports the activation of phagocytic 
elimination of MTB [24]. 
Serum IL-2 level significantly decreased in 
patients with pulmonary TB following two mon-
ths of routine treatment compared to IL-2 level 
prior to treatment. Circulating IL-2 concentration 
was significantly increased in patients with pul-
monary TB following two months of treatment 
in comparison with the third group. Considering 
these changes, we can assume Th1-lymphocyte 
activity decrease in this group of patients. It may 
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indicate a certain stabilization in patients with 
pulmonary TB taking into account the fact that 
serum IL-2 level is still significantly higher com-
pared to healthy subjects.
Different genotypes of the IL-2 gene that we 
saw in our research may demonstrate genetic 
predisposition to the disease development. This 
hypothesis has been proved through analysis of 
association between polymorphisms and circula-
ting cytokine levels in patients with pulmonary 
TB, which contributes to pathological changes 
in serum IL-2 levels in patients with TB on ad-
mission to hospital and following two months of 
chemotherapy.
Furthermore, we observed statistically signifi-
cant decreased serum levels of anti-inflammatory 
cytokines IL-4 and IL-10 compared with the third 
group at the point of treatment onset. It indicates 
that Th2-lymphocyte activity was decreased prior 
to treatment. These changes may be associated 
with pronounced activation of Th1-lymphocy-
tes during augmentation of immunity against 
tuberculosis in patients with pulmonary TB at 
the onset of chemotherapy. Changes of IL-4 and 
IL-10 conducted after two months of therapy, may 
be associated with the activation of Th2-lympho-
cytes and, as a  result, a certain stabilization of 
Th1-lymphocytes. Evaluation of serum cytokine 
levels in patients following two months of anti-TB 
therapy and equivalent parameters in healthy 
subjects showed significant IL-4 level reduction 
in the first group, indicating relative insufficiency 
of IL-4 level restoration during the second month 
of treatment. 
C589T polymorphism of the IL-4 gene and 
G1082A polymorphism of the IL-10 gene are 
deemed the most important for immunogenetic 
mechanisms of inflammation in TB patients [25, 
26]. We conclude that homozygous genotype (CC) 
of the IL-4 gene and homozygous genotype (GG) 
of the IL-10 gene have a protective effect against 
infiltrative pulmonary TB.
Moreover, studied cytokine levels and poly-
morphisms may indicate an impact of polymor-
phisms on aforementioned interleukins produc-
tion at the treatment onset and over a  course 
of treatment that has been already shown in 
previous studies [27]. This finding was suppor-
ted by significant changes of serum cytokines 
concentrations in patients with pulmonary TB on 
admission to hospital and following two months 
of chemotherapy.
Thus, heterozygous and mutational homozy-
gous genotypes of the IL-2, IL-4 and IL-10 genes 
determining production level of studied interleu-
kins represent an important risk factor of suscep-
tibility to pulmonary TB development and disease 
progression into chronic phase. Heterozygous 
genotype activation of studied interleukin poly-
morphisms can contribute to MDR TB develop-
ment through non-stabilized immune response of 
human body and resistant MTB strains infection 
prior to chemotherapy and over a course of treat-
ment. Furthermore, it has not been demonstrated 
what mutations exactly are of crucial importance. 
We suppose that combination of genotypes but 
not separate genotypes of the genes plays a key 
role. The influence of genotypes combinations on 
susceptibility to infection and sustained bacterial 
infection is among the perspectives in IL-2, IL-4 
and IL-10 immunogenetic studies.
Due to low numbers of study participants our 
results should be treated as preliminary.
Conclusions 
1.  Serum IL-2 level was significantly increased 
in MDR TB patients compared to the group 
of patients not colonized by resistant MTB 
to anti-TB drugs at treatment onset and fol-
lowing two months of treatment. Circulating 
IL-4 and IL-10 levels were significantly in-
creased in patients not suffering from MDR 
TB compared to the group of patients with 
resistant TB at treatment onset and following 
two months of antimycobacterial chemothe-
rapy.
2.  Low IL-4, IL-10 secretion and high serum 
IL-2 alterations were significantly associated 
with homozygous (TT) and heterozygous 
(CT) genotypes of the IL-4 gene, homozygous 
(AA) and heterozygous (GA) genotypes of the 
IL-10 gene as well as homozygous (GG) and 
heterozygous (TG) genotypes of the IL-2 gene 
in patients with infiltrative pulmonary TB.
3.  Genotype CC of C589T polymorphism in the 
IL-4 gene, genotype GG of G1082A polymor-
phism in the IL-10 gene and genotype TT of 
T330G polymorphism in the IL-2 gene are 
immunogenetic factors exerting a protec-
tive effect in patients with pulmonary TB. 
Heterozygous (TG) genotype of T330G poly-
morphism in the IL-2 gene, CT genotype of 
C589T polymorphism in the IL-4 gene and GA 
genotype of G1082A polymorphism in the IL-
10 gene were significantly the most frequent 
in the MDR TB patients. Homozygous (TT) 
genotype of C-589T polymorphism in the 
IL-4 gene, AA genotype of G-1082A polymor-
phism in the IL-10 gene and GG genotype of 
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T-330G polymorphism in the IL-2 gene were 
significantly the most frequent in the group 
of patients not suffering from resistant TB.
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